[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
From the Centers for Disease Control and Prevention
February 13, 2002

Evaluation of Postexposure Antibiotic Prophylaxis to Prevent Anthrax

JAMA. 2002;287(6):710. doi:10.1001/jama.287.6.710-JWR0213-3-1

MMWR. 2002;51:59

In response to the recent bioterrorist attacks associated with intentional release of Bacillus anthracis, approximately 10,000 persons potentially exposed to anthrax in Connecticut, Florida, New Jersey, New York City, and Washington, D.C., were recommended to take at least 60 days of postexposure antibiotic prophylaxis. Surveillance for adverse events and adherence to antibiotics has been conducted through surveillance and cross-sectional studies. CDC is evaluating the program to distribute antimicrobial agents and assessing adverse events and adherence.

The objectives of this evaluation are to assess the provision of antimicrobial agents and educational materials to affected persons, to determine adverse events associated with the antimicrobial agents, and to characterize adherence to the recommended regimen. The information from this evaluation will be critical to CDC's effort to improve the technical assistance and supplies needed with future anthrax postexposure prophylaxis campaigns and to comply with Food and Drug Administration regulations for monitoring for adverse events.

CDC has contracted RTI International to conduct brief telephone interviews of all persons for whom postexposure antibiotic prophylaxis was recommended. Interviews were scheduled to begin in late January 2002 and will continue for approximately 8 weeks. Additional information about the program evaluation is available from CDC, telephone 404-639-3158.

×